These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 34944094)

  • 1. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
    Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
    L√łnning PE; Nikolaienko O; Pan K; Kurian AW; Eikesdal HP; Pettinger M; Anderson GL; Prentice RL; Chlebowski RT; Knappskog S
    JAMA Oncol; 2022 Nov; 8(11):1579-1587. PubMed ID: 36074460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
    Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X
    Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
    Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer.
    El-Arabey AA; Abdalla M
    Hum Cell; 2022 Jul; 35(4):1298-1300. PubMed ID: 35459984
    [No Abstract]   [Full Text] [Related]  

  • 7. Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.
    Eismann J; Heng YJ; Waldschmidt JM; Vlachos IS; Gray KP; Matulonis UA; Konstantinopoulos PA; Murphy CJ; Nabavi S; Wulf GM
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):503-514. PubMed ID: 31745703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
    Wallbillich JJ; Morris RT; Ali-Fehmi R
    Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
    Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
    Mittempergher L
    Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
    Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
    Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
    Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
    Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
    J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
    J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.
    Mittempergher L; Piskorz AM; Bosma AJ; Michaut M; Wisman GBA; Kluin RJC; Nieuwland M; Brugman W; van der Ven KJW; Marass F; Morris J; Rosenfeld N; Jimenez-Linan M; de Jong S; van der Zee AGJ; Brenton JD; Bernards R
    PLoS One; 2020; 15(7):e0235766. PubMed ID: 32639993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutional
    Al-Moghrabi N; Al-Showimi M; Alqahtani A; Almalik O; Alhusaini H; Almalki G; Saad A; Alsunayi E
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.